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Clinical organ transplantation between geneticallydisparate individuals presently
requires nonspecific immunosuppressive agents to prevent rejection. However, the
use of such agents risks morbidity and mortality from a range of associated side
effectsand does not always guarantee success ofthe graft. Therefore, there isa need
to establish methods of"donor-specifictransplantation tolerance"that would not re-
quire long-term immunosuppressive therapy. Since the first report ofspecific trans-
plantation tolerance, induced in newborn mice by injection ofdonor bone marrow
(BM)1(1), there has been much interest in achieving the same in the adult. Ifit were
possible to recreate in the adult the immunologicalnaivetyoftheneonate, then similar
marrow transplants could be used to tolerize for organ grafts.
Many attempts have been made to do this. At the experimental level the most
successful have involved the use of lethal whole body irradiation (2, 3); total lym-
phoid irradiation (4); ablativechemotherapy (5); antilymphocyteantisera (6, 7) and
in one case ofPl-(PI x P2)F1 combination, by using antidonor MHC mAbs (8);
all coupled with transplantation of BM from the allogeneic donor. In essence, the
common theme ofthese strategies was to allow the donor marrow to establish some
degree ofhemopoieticchimerism. Theubiquitous distribution ofchimeric hemopoietic
cells clearly favors them as vehicles to present donor antigens fortolerance whatever
the mechanisms involved.
We demonstrate here that transplantation tolerance can, in a number of strain
combinations, be induced in the adult mouse by combining BM transplantation
(BMT) together with parenteral administration ofCD4 and CD8 mAbs. We show
this forcombinations differing in multiple "minor" transplantation antigens and for
combinations differing in minors plus class I MHC. We investigate the need for
donor and recipient T lymphocyte depletion; document true tolerance in recipient
T cells; and provide evidence suggesting differential handling ofminor vs. major
histocompatibility antigens in the antibody-treated recipients. All this was possible
in animals that had not received either irradiation or myelosuppressive drugs. Sur-
prisingly, Tcell tolerance across Mls differenceswas not accompanied byany reduc-
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tion in expression of V06 gene products in the peripheral immune system . These
findings should serve as a basis for the evolution of improved strategies to impose
tolerance for successful organ transplantation.
Materials and Methods
Animals.
￿
Mouse strains used in the experiments are listed in Table I. They were bred
and kept in the conventional facilities of the Pathology Department, Cambridge University,
and were used in sex- and age-matched groups.
Monoclonal Antibodies.
￿
The two pairs of synergistic mAbs used in the experiments were
all of rat IgG (rlgG)2b isotype. YTS 191 .1 and YTA 3.1 are CD4 specific (references 9, 10).
Of the two CD8 mAbs, YTS 169.4 is anti-Lyt-2 and YTS 156.7 is anti-Lyt3. (reference 9
and unpublished data). The rIgG2a mAbs YTS 177.9 (CD4) and YTS 105.18 (anti-Lyt-2)
known to be nondepleting antibodies were developed in this laboratory (Qin, S., S. Cobbold,
Y. M. Kong, H. Waldmann). All antibodies were obtained from (DA x LOU)F, rat ascitic
fluid, purified by ammonium sulfate precipitation and dialyzed into PBS.
Preparation ofmAb F(ab)z Fragments.
￿
F(ab')2 fragments of YTS 191.1 and YTS 169.4 were
made by the method of Rousseaux et al. (11). Antibodies in 0.1M sodium phosphate were
digested with Type XVII protease from Staphylococcus aureus (Strain V8; Sigma Chemical Co.,
Poole, UK) at an enzyme/substrate ratio of 1 :200 (wt/wt). The digestion was carried out at
37 °C for 4 h, stopped by freezing. Antibody F(ab')2 fragments were purified by gel filtra-
tion on a 2.5 x 95 cm column packed with Ultragel AcA 44 (LKB; Villeneuve-la-Gavenne,
France). The purity of F(ab')2 products was confirmed by SDS-PAGE and by complete in-
hibition of in vitro complement lysis by parental antibodies as reported elsewhere (12).
Bone Marrow Transplantation.
￿
Bone marrow cells were flushed from donor femoral and tibia]
bonesand washed with cold Eagles' Hepes medium. Live cells were counted with trypan blue,
and adjusted to appropriate viable cell concentrations. T cell-depleted BM were obtained
from thymectomized mice that had been given two CD4 and CD8 synergistic mAb pairs
(2 mg/mouse, i.e., 0.5 mg of each mAb), or from normal mice given the mAbs 2 d before
they were killed. In some experiments, an equal number of spleen cells from the same marrow
donors were added into the inoculum. 0.2 ml of the cell suspensions was injected intrave-
nously into recipient mice.
Skin Grafting
￿
Skin grafts were performed as previously reported. (9) In short, donor tail
skin grafts (0.5 cm x 0.5 cm) were transplanted onto the lateral thoracic wall ofthe recipient,
then covered with clean gauze and plaster for 7 d. The graft survival was documented daily
thereafter, and the results were analyzed by Log-Rank method (13).
Mixed Lymphocyte Culture and Cell-mediated Cytotoxicity In Vitro.
￿
To achieve an adequate in
vitro response to minor histocompatibility antigens, responder mice were primed in-
traperitoneally with irradiated spleen cells of the stimulator strain 1 wk before testing. In
MLC, responder spleen cells (2 x 106/ml) were incubated with irradiated (3,000 rad) stimu-
lator cells in Iscove's modified Dulbecco's medium containing 5% FCS at 37°C, 5% C02
in a humidified incubator. On day 3, 5 p,l 1251-deoxyuridine (10 uCi/ml; Amersham Corp.,
TABLE I
Mouse Strains Used in the Experiments
H-2
K A E D "Background"
CBA/Ca k k k k CBA, Mlsb
B10.BR k k k k B10
B10.A k k k d B10
B10.D2 d d d d B10
BALB/c d d d d BALB
BALB/k k k k k BALB
AKR/J k k k k MlsaQIN ET AL.
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Amersham, UK) was added into each well. The cells were harvested 6 h later,
1251 incorpo-
ration was measured on a Philips Automatic Gamma Counter (Philips, Eindhoven, The Nether-
lands). The cytotoxic responses were generated by incubating the responder cells with stimu-
lator cells as for the MLC, but in RPMI 1640, 5% FCS for 6 d in 24-well Linbro plates.
Cells were harvested, washed twice, and resuspended in U-bottomed 96-well microtiter plates.
Con A blast target cells (106/ml) labeled with 30 p,Ci/ml "Cr (Amersham Corp.) were in-
cubated with various number of effector cells (final volume, 200 J,1/well) for 4 h. 100 ul of
supernatant was then collected and the radioactivity was counted on a Philips Automatic
GammaCounter. The specific release was calculated by the following formula: Percent specific
release = 100 x [(e-s)/(t-s)] . where e is the sample count per minute, s is the spontaneous
release oftarget cells in medium only, t is the total counts by resuspending cellsafter incuba-
tion. All samples were performed in triplicates.
Detection ofDonor Chimerism.
￿
The demonstration of donor B cell chimerism was based on
a difference in Ighl loci (encoding IgG2a) between CBA (Ighla) and B10.BR (Ighlb), by
a hemagglutination inhibition assay. Normal human RBC washed in saline were coupled
with a mouse IgG2a mAb (MAR 18.5, Ighlb, reference 14) in the presence ofchromic chlo-
ride. Sample sera were diluted in flexible U-bottomed plates (Falcon Labware, Oxnard, CA)
with a rabbit anti-mouse Ighlb antiserum (a kind gift from Dr. C . Elson, Bristol University,
Bristol, UK). After 10 min of incubation, Ighlb RBC were added into each well, and the
agglutination results were observed 1 h later. A series ofCBA sera laced with a defined amount
of B10.BR serum were used in each assay to give a standard inhibition curve from which
the percentage of donor Ig chimerism was calculated. This method enabled us to detect down
to 0.2% B10.BR serum.
To follow T cell chimerism, AKR/J BM cells were injected into CBA/Ca mice along with
the mAb treatment regime. 4 wk after transplant, the mice were bled and peripheral
mononucleated cells were stained with biotinylated antiThy-1.1 and antiThy-1.2 (reference
15) mAbs, followed by streptavidin-FITC (Amersham Corp.). The percentage of binding
was analyzed by a Cytofluorograf (model 50-H ; Ortho Diagnostic Systems, Inc., Westwood,
MA) and Ortho 1250 computer.
Two-Color Flow Cytometry.
￿
Mouse lymph node cells were incubated with CD4 (YTS 191.1
+ YTA 3 .1) or CD8 (YTS 169.4 + YTS 156.7) in spent tissue culture medium. Biotinylated
44-22-1 (16) was used to stain V(06 chain of the T cell receptor. The green fluorescence was
developed by FITC-conjugated Norig 7.16 (anti-rat IgG2b, reference 17), the red fluores-
cence by streptavidin-phycoerythrin (Serotec, Kidlington, UK). The data were analyzed by
a Cytofluorograf (Ortho Diagnostic Systems, Inc.), and 1250 computer.
Results
The Effect of CD4 and CD8 mAb Therapy on Skin Graft Rejection.
￿
The following ex-
periments analyze the consequences ofadministering immunosuppressive antibodies
together with transplants ofdonor mouse BM on survival of donor-type skin grafts.
To clearly distinguish the effects of the combination (mAbs + BM) from that of
the antibodies alone, we first determined how long the immunosuppressive effects
of the mAb cocktail would last. This we did by grafting allogeneic skin at different
times after the antibody injection . The model system used B10.BR (H-2k) tail skin
grafts onto CBA/Ca (H-2k) recipients; in other words, incompatibility at multiple
minor loci. Normal CBA/Ca mice mount a rapid rejection response to B10.BR skin
with a median survival time (MST) of 10 d (Fig. 1) . The mAb cocktail of two CD4
(YTS 191.1 and YTA 3 .1) and two CD8 mAbs (YTS 169.4 and YTS 156.7) reactive
to nonoverlapping epitopes of the CD4 and CD8 molecules were injected to achieve
maximal immunosuppression. A mixture of 1.2 mg (0.3 mg of each of the four) mAb
was given in three injections over 5 d. As can be seen in Fig. 1, this treatment
significantly prolonged the MST of grafts transplanted up to 2 wk after antibody
injection. However, first set skin grafts applied 3 wk after the completion of mAb782
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FIGURE 1.
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Rejection ofBIO.BR
skin grafts by CBA/Ca mice at
different times after C134 and
CD8 antibody treatment.
CBA/Ca (n = 6) mice were in-
jected with threedoses of CD4
and CD8 mAbs over 5 d.
B10.BR skin grafts were given
at 1 wk (0), 2wk (0)and3wk
(O)afterthelast mAbinjection.
Thecontrolgroup (A)received
no antibody. Analyses of MST:
controls versus mAb + skin
graft at 1 wk,p4 0.007; vs. 2-
wk grafts, p 4 0.01; vs. 3-wk
grafts p 4 0.7.
therapy were rejected as rapidly (MST, 10.5 d) as grafts onto untreated recipients .
This return of immunocompetence allowedus to rapidly assess the tolerizing poten-
tial of BM when added to the same mAb cocktail. This we could do by performing
skin transplantation 3 wk after administration of the inoculum. Any delay beyond
the control time would then reflect the tolerizing contribution of the BM.
CD4 andCD8 mAb Therapy Permits theDevelopmentofDonor-speck Tolerance afterBone
Marrow Transplantation. T cell-depleted B10.BR BM and spleen cells were infused
into CBA/Ca mice undertheumbrella ofmAb therapy givenas above. Mice so treated
accepted B10.BR skin grafts applied 3 wk later (MST >200 d) (Fig. 2 a). Spleen
cells were included in the inocula simply to maintain the comparability to the clas-
sical model. We laterestablished that bone marrow cells alone were sufficient to in-
duce tolerance and therefore spleen cells were omitted from most of the subsequent
experiments.
All threeelements ofthe tolerizing inoculum (the twosets ofmAbs andthe marrow
cells) were essential. Mice given marrow and no mAb or marrow and only one of
the sets of mAbs (CD4 or CD8) rejected the skin within 20 d (Fig. 2 b). Substitution
of the marrow with another source of donor antigen (skin) was ineffective (Fig. 2
c). In fact, grafting the test (second) skin resulted in prompt rejection of both the
first and the test grafts.
To establish whether the prolonged graft survival was truly a result of tolerance
rather than ofgraft immunogenicity decaying with time, second B10.BR grafts were
transplanted 130 d after the first. These were all accepted together with continued
survival of the first grafts. Clearly, the recipient mice were tolerant of donor tissue
(Fig. 2 b).
Further studies (our unpublished data) showed that for this strain combination
at least 106 Tdepleted marrow cells and at least an average of 250 /Ag of each of the
mAb were necessary. We did not separately determine the relative requirements for
CD4 and CD8 mAbs. However, our previous work (9) has documented that <10
/Ag of CD8 mAb (YTS 169.4) is an effective depleting dose; whereas at least 200
hg of the CD4 mAb (YTS 191.1) is required for equivalent depletion. Therefore,
the present results probably reflect the requirement for a high CD4 mAb dose.
Thus farwe have, forreasonsofinterpretation, purposelyseparatedthemarrow/mAbsee
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Tolerance to mul-
tiple minor transplantation an-
tigens induced by the combina
tion ofCD4/CD8 mAb therapy
and BMT (A) Normal CBA/Ca
s0
￿
(n = 12) mice were given a total
of 1.2 mg of CD4 and CD8
mAbs on days 0, 3, and 5, plus
10' BM and 10' splenic B10.BR
Tdepleted cells 2 h after the first
®
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All groups rejected BALB/c skin 2nd skin graft
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within 12 d ("). (B) CBA/Ca Be -
mice (n = 6) received a total of
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2.4 mg CD4 mAbs (1 .2 mg of
YTS 1914 and 12 mg YTA 31; . . . o..
A); 2.4 mg of CD8 mAbs (1.2
mg of YTS 169.4 and 1.2 mg
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YTS 156.7; O); 2.4 mg ofCD4
o
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and CD8 mAbs (0.6 mg ofeach
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of the four mAbs; ") in three e
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injections as above or no anti-
body (0). B10.BR BM/ spleen
cells and skin were given as
above. MST: CD4-depleted,
16 d; CD8-depleted, 16 d. In the
group maintaining long-term
grafts ("), a second B10.BR
skin graft was transplanted 130 d
C
￿
after the first. Both the first and
second grafts on each animal (n
= 6) have remained healthy for
a further 200 d (p t 0.001). (C)
Three doses of CD4 and CD8
mAbs were given to CBA/Ca
mice as before. On the day of 1.e
TIME (DAYS)
￿
the first antibody injection,
B10.BR skin grafts were trans-
planted onto two groupsofmice
(six mice/group). Another group of six CD4+CD8-depleted mice received instead of skin, 2 x 101 BM
and spleen cells from T-depleted B10.BR mice. 3 wk later, the BMT group (O) and a skin-bearing group
(") were grafted with BlO.BR tail skin. Animals that received the second skin grafts rejected both the
original and the test grafts simultaneously. MST: original grafts, 31 d; test grafts, 9 d; single skin graft
group ( ") 63 d (p G 0.06); mAb+BMT group 3100 d.
Be see
induction therapy from the skin graft readout by a 3-wk interval. In practice, the
whole induction protocol and test skin graft (at least for the B10.BR into CBA/Ca
combination) can be compressed into a single day and tolerance can be achieved
as easily (Table II). This findinghasobviousclinical implications. On theotherhand,
the skin transplant can be postponed for up to 12 mo after BMT, with skin graft
survival ofover a further 100d (Table II), suggesting thetolerizing effect ofthepresent
regime can be both immediate and long lasting.784
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TABLE II
Time Between BMT, nzAb Therapy, and Skin Grafting for
Successful Tolerance Induction
CBA/Ca mice (five to six/group) were given 107 T-depleted B10.BR BM cells
on day 0. Three injections ofCD4 and CD8 mAbs were given and B10.BR skin
was grafted on days as indicated relative to BMT.
However, the time during which mAbs were given seemed very critical for toler-
ance induction. Asis shown in Table II, the same course ofmAb therapycompleted
3 d before or initiated 3 d after BMT failed to facilitate tolerance; all the mice so
treated rejected their donor skin in a secondary set fashion (Table II).
Is the Depletion ofBoth the CD4 and CD8 Subsets Essential?
￿
Recently in a different
tolerance system it has been observed that F(ab')2 fragments of CD4 mAbs were
sufficient for tolerance induction to human gamma globulin (HGG) (12) and rat
Ig (18). In these cases, depletion ofCD4+ cells was not required for the induction
oftolerance. To establish whether depletion was essential in the present model, we
tested whether F(ab')2 fragments, given at high doses daily for 1 wk, could also
create an environment permissive for development of BM-induced tolerance. In
this experiment only one ofthe CD4 or CD8 mAb fragments ofeach synergistic
pairwasadministered. Thismade itpossibletouse the partner antibody formonitoring
depletion in the"fragment"-treated groups. B10.BRBM cells were given toCBA mice
together either with complete antibodies as above, F(ab')2 fragments of one mAb
plus intact mAbs to the complementary antigens or both CD4 and CD8 mAb
F(ab')2. 3 wk after the last mAb injection, all animals and control groups were
TABLE III
Host T Depletion and Tolerance Induction
Percent cells:
' CBA/Ca mice (n = 6) were given 107/mouse B10.BR BMCs on day 0. Intact antibodies (Ig)
were given as synergistic pairs, 1 mg/mouse in three doses on day 0, 2, and 4. CD4 F(ab')2
was made from YTS 191 .1 and CD8 from YTS 169.4. A total of6 mg/mouse F(ab')2 was
given in six injections over 1 wk.
$ Blood smears were made 3 d afterthe last mAb injection and stained with immunofluorescence
by respective mAbs for different epitopes of CD4 and CD8 molecules.
mAb on days BMT on days Skin grafting on days MST
0,3,5 0 0 >300
0,3,5 0 28 >300
0,3,5 0 180 >200
0,3,5 0 370 >100
3,6,8 0 28 9.8
-7,-5,-3 0 28 8.5
mAb treatment' CD4' CD8' Survival of donor skin
MST
CD41g + CD81g <1 <1 >120
CD4Ig + CD8 F(ab')2 <1 21 .1 >120
CD4 F(ab')2+CD8Ig 40.5 <1 8.7
CD4 F(ab')2 35 .8 11 .2 9.2
CD8 F(ab')2 32 .3 10.9 8.6
C134 Ig <1 20.3 11 .5
CD8Ig 42.2 <1 8.9TABLE IV
Difference of Rat IgG2a and IgG2b mAbs on Cell Depletion and Tolerance Induction
PBL lymphocytes
QIN ET AL.
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Normal CBA mice (n = 6) were given 15 d mAb treatment (0.5 mg total mAb/day) as indicat-
ed and 10 7 B10.BRBM cells at the beginning oftreatment . 5 d after the last mAb injection,
mice from each groupwere bled and PBLlymphocytes analyzed by flow cytometry . Numbers
given are percentage of positive cells (mean of fluorescence intensity [MFI]) . 3 wk later they
were grafted with BIO.BR tail skin .
grafted with B10.BR skin . The results are given in Table III . Surprisingly theCD8
mAb can be wholly replaced by F(ab')2 fragments when accompanied by intact CD4
mAbs . However, mice givenCD4 F(ab')2 rejected donor test skin irrespective of the
nature ofCD8 mAb offered .
An alternative way of treating with CD4 and CD8 mAbs without incurring cell
depletion is to use nonlytic rat IgG2amAbs (Qin, S., et al ., manuscript in prepara-
tion). In Table IV it can be seen that injection of these mAbs resulted in antigenic
modulation butnot depletionoftherelevant subsets . As with therIgG2b fragments,
the rIgG2aCD8mAbcould contribute to tolerance ifcombined with a rIgG2bCD4
mAb . Remarkably, the rIgG2a CD4 mAb could also enable tolerance ifcombined
with arIgG2bCD8mAb . However, thecombinationof rIgG2aCD4 andCD8mAbs
was surprisingly ineffective .
Alloreactive TCellsMust Be Removedfrom theMarrow/Spleen Inoculum to Guarantee Toler-
ance. The tolerogenicity ofthe B10.BRBM seemed to be impaired by the presence
of donorTcells . This isshown in Fig. 3 where only 4 of 11 (27%)CBA/Ca recipients
FIGURE 3. Transplantation
tolerance achieved in MHC
class I andminormismatches .
CBA/Ca mice (n = 6) were an-
tibody treated as above : 2 x
10 7 B10.A BM on the first day
of mAb treatment . B10.A,
B10.BR and BALB/c skin grafts
were transplanted 3 wk later.
MST : B10.A (O) >90 d;
B10.BR (A)>90d; BALB/c (" )
12 .1 d. Control (mAb only A)
11.5 d; BM only (" ) 9.1 d .
Treatment CD4' CD8' Thy-1' Graft survival
% MFI % MFI % MFI MST
IgG2a CD4 31 .5 86 1 .3 157 52 .5 607 >120
IgG2b CD8
IgG2a CD4 26 .4 86 12 .5 76 56 .7 503 12
IgG2a CD8
IgG2b CD4 1 .7 78 15 .3 115 19 .8 552 >120
IgG2a CD8
IgG2b CD4 4.3 121 6.5 129 3 .5 193 >120
IgG2b CD8
PBS 39 .8 157 12 .5 185 47 .0 430 9.8786
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were tolerized by nonpurged marrow/spleen inocula . In contrast, purged marrow/
spleen produced tolerance in all recipients . Equivalent transplants from (CBA x
B10.BR)F1 donors were able to induce tolerance whether or not T cells had been
purged . Similar results were obtained in two consecutive experiments . As will be
demonstrated below, the nontolerant animals showedno evidence ofdonorchimerism .
We can only assume that our mAb treatment of recipient was marginal and that
some donoralloreactive cells were spared . We have notinvestigated whether the same
would hold true for other strain combinations .
Extending Tolerance to Class IMHCplusMultiple Minor Differences.
￿
Theoriginal descrip-
tion of transplantation tolerance in the neonate (1) used the strain combinations(CBA
x A)F, into CBA (H-2a+k-+H-2k) . We have similarly found that tolerance for B10.A
into CBA/Ca (H-2a--"H-2k : class I + multiple minor differences) can also be
achieved in the adult using theCD4 andCD8mAbs to help B10.A marrow engraft-
ment (Fig . 4) . It is interesting to note that the mice transplanted with B10.A marrow
also became tolerant to B10.BR grafts . This suggests that minors were beingreprocessed
as previously documented in fetal liver radiation chimeras (19) .
Failure to Tolerize Over CompleteMHC + Minor Differences .
￿
TableV shows results
of an experiment in whichwe attemptedto induce tolerance ofBALB/c mice to B10.BR .
BALB/c mice received a standard course ofmAb treatment and the accompanying
marrow graft from B10.BR donors . 3 wk later these mice -were grafted with skin
from B10.BR and B10.D2 donors . B10.BR skin was rejected rapidly(MST 10 d) by
mAb + BM-treated mice, demonstrating that no tolerance had been induced in
this combination . Interestingly, 1110.132 skin was accepted forMST of 56 d by the
same mice . Furthermore, they all rejected BALB/k skin, suggesting that there was
tolerance to B10 minors in association with H-2d but not to H-2k alloantigens . A
similar result was obtained when CBA/Ca mice were transplanted with BALB/c
marrow under cover ofCD4/CD8mAbs; theybecame poorly responsive to BALB/k
FIGURE 4 .
￿
The presence ofal-
loresponsive T cells in the
marrow graft interfered with
tolerance induction . CBA/Ca
mice simultaneously receiving
CD4 and CD8 mAb therapy
were injected with marrow and
spleen cells from normal
B10.BR(A, n = 11), Tdepleted
B10.BR (O, n = 6), normal
(CBA x B10.BR)F l (,6k, n =
6), or Tdepleted (CBA x
B10.BR)F 1 (7, n = 6) . 3 wk
after BMT, B10.BR skin was
grafted. All grafts survived >16
wk except for mice given
B10.BR marrow without T
depletion, in which 7 of 11
(73%) grafts were rejected
(MST. 10 d, versus (CBA x
B10.BR)F 1 groupp<0.002). A
control group received mAbs
but no cells (" , n = 6), and
these rejected B10.BR grafts
with an MST of 14 d .QIN ET AL.
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TABLE V
Split Tolerance to H-2 and Minor Antigens
Normal BALB/c mice (n = 6) were injected with CD4 and CD8 synergistic mAb pairs, 1 mg
in total in three doses. 107 B10.BR BM were given intravenously after the first antibody in-
jection. Skin grafts were performed 3 wk after the last antibody injection.
skin but rejected BALB/c grafts (our unpublished data). In both cases the unrespon-
sive state to donor minors associated with "self-MHC" was not permanent. Most
likely, this reflects the disappearance of processable "minor" antigenthat follows re-
jection ofdonor marrow. Presumably, tolerance waned as the level of tolerogen di-
minished. These data suggest that whatever the mechanism of marrow rejection in
unirradiated MHC-mismatched combinations, there seems to be two fundamen-
tally different and independent immunological phenomenaoperatingafter the marrow
infusion. One produces priming to donor MHC antigens and the other results in
tolerance (albeit shortlived) to donor minors when presented on host-type MHC.
The Lack ofSpecific Alloreactivity In Vitro of Lymphocytes from Tolerant Animals.
￿
The
state of tolerance at thelevel of graft acceptance was reflected in the failure of recip-
ient cells to demonstrate alloreactivity towards tolerizing antigens in vitro. Spleen
cells from tolerant mice (B10.BRinto CBA/Ca) remained unresponsive when primed
in vivo then stimulated in vitro with B10.BR cells while they responded normally
to third-party alloantigens (Table VI). Interestingly, spleen cells from tolerant animals
TABLE VI
In Vitro Specific Unresponsiveness of Spleen Cells from CBA Mice
Rendered Tolerant by BMT and mAb Therapy
3,000 rad irradiated spleen cells .
l Count per minute of IUdR uptake (SD of geometric means).
$ Cell-mediated lympholysis. Figures are percentage of specific "Cr release at
E/T ratio of 40:1 (SD of arithmetic means).
~~ Mice rendered tolerant as in legend to Fig. 2, holding perfect B10 .BR skin
for >100 d.
Host mAb
Treatment
BM Skin Graft survival
MST
BALB/c CD4 + CD8 B10 .BR 1310.13R 9.8
BALB/c CD4 + CD8 B10 .BR 1310.132 56
BALB/c CD4 + CD8 B10 .BR BALB/k 11 .2
BALB/c CD4 + CD8 None B10.BR 10.2
BALB/c CD4 + CD8 None 1310.132 13.0
BALB/c CD4 + CD8 None BALB/k 11 .4
Responder Stimulator' Proliferationl CML4
Tolerant CBA11 B10.BR 979 (1 .0) 0
BALB/c 6,004(l.1) 41 (9.7)
Normal CBA 632 (1 .1) ND
None 1,196 (1 .2) ND
Primed CBA B10.BR 4,353 (1 .5) 34 (5.6)
BALB/c 7,629 (1 .1) 28 (8.4)
Tolerant CBA 5,188 (1 .1) ND
None 1,161 (1 .2) ND788
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TABLE VII
Donor Ig Chimerism after BMT
Animals were treated as in Fig. 4 legend.
1 Donor IgG2a chimerism in recipients (n = 6) detected by hemagglutination inhibition analyses.
S Individual results: 0, 0, 0.4, 0.8, 0.8; the first three mice had rejected their skin grafts. Compared with
T-depleted group, p 4 0.05.
could stimulate the primed CBA cells. This implies that donor-type antigens were
present within the tolerant animals some 120 d after induction of tolerance.
Chimerum Is Necessaryfor Tolerance.
￿
In the multiple minormismatch combinations
that we have used there is no simple and sensitive way to type the majority of
hemopoietic cells. We therefore sampled the Ig allotype as a marker ofdonor B cell
chimerism. This analysis was based on the different expression of IgG2a allotypes
between black strains of mice (Ighlb) and CBA/Ca mice (Ighla). In Table VII we
document such chimerism for the experimental groups described in Fig. 4. 1 wk
after BMT we could detect donor-type IgG2a in the sera of all tolerized mice. This
reached peak levels at 2 wk (2-5 % of total serum IgG2a) and remained steady there-
after. All animals that maintained their grafts permanently exhibited prolonged B
cell chimerism, although in some, donor allotype fell to below detectable levels
(<0.2%) after 200 d (not shown). In contrast, we have never been able, in
B10.BR-"CBA/Ca combination, to detect donor-type Ig in animals that had received
marrow without the mAb cocktail. However, we have found a combination,
B10.BR-(CBA x BALB/c)FI, where chimerism was maintained despite skin graft
rejection (Table VIII). To distinguish if this was due to the presence of skin-specific
antigens or a failure to completely tolerize recipients to antigens well expressed on
the skin, an extra sublethal dose of irradiation was given to permit the development
of ahigher level ofchimerism. Mice that underwent such treatment developed4-5
donor Ig chimerism and then accepted donor skin.
TABLE VIII
Summary of Donor Ig Chimerism and Skin Graft Survival
Ighl chimerism analyzed 4 wk after BMT.
Skin grafts performed 3 wk after mAb treatment.
S 1-2 x 107 T-depleted BM cells given at the time of mAb treatment.
Recipients were given 150 rad in addition to mAbs before BMT.
Treatment'
Donor Recipient
Percent
1 wk
of chimerism (mean
4 wk
t SD)l
8 wk
T-depleted B10.BR T-depleted CBA 0.3 ± 0.2 2.0 ± 0.5 2.1 f 0.6
Normal B10 .BR T-depleted CBA 0.4 t 0.2 1 .5 f 0.7 0.4 ± 0.44
T-depleted (CBAxB10.BR)Fl T-depleted CBA 0.3 ± 0.2 4.7 t 2 .8 5.6 t 2 .8
Normal (CBAxB10.BR)Fl T-depleted CBA 0.2 t 0.2 4.7 f 2 .8 3 .2 t 1 .3
T-depleted B10.BR normal CBA 0 0 0
Donor Recipient Treatment
Percent chimerism`
(mean ± SD)
Graft survivall
(MST days)
B10.BRS CBA CD4+CD8 3 .2 t 1 .1 >200
B10 .A CBA CD4+CD8 2 .5 t 0.4 >200
B10 .BR (CBAxBALB/c)Fl CD4+CD8 2 .1 t 0 .3 12 .3
Bl0 .BR (CBAxBALB/c)Fi CD4+CD8+TBI11 5 .8 t 1 .2 >60QIN ET AL .
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TABLE IX
T Cell Chimerism afterBMTand mAb Treatment
CBA mice (n = 6) were treated with 1 mg/mouse CD4 and CD8 mAbs and 10 7
T-depleted AKR/J BM cells were given . 8 wk later, the phenotype of the recipient
PBL was determined by flowcytometry .
Recipient T Cells Become Tolerant.
￿
The fact that we had ablated recipient T cells
in most of the experiments meant that there was a possibility that the new T cells
would be wholly donor derived . If that were the case then we would not be able
to claim tolerance induction in recipientT cells . To permit measurements ofT cell
chimerism in this model of tolerance we extended the studies to follow the conse-
quences ofAKR/J marrow grafts into CBA/Ca . In addition to minor transplanta-
tion antigen incompatibilities, these strains differ in Thy-1 allotypes . This allowed
for measurement ofchimerism in theT lineage . AKR/J marrow tolerizedCBA/Ca
mice (skin graft survival >200 d) as expected (data not shown) . From 4 wk after
BMT, recipient mice were bled and peripheral mononuclear cells were stained with
Thy-1 allelic-specific mAbs . Table IX demonstrates that from 8 wk after BMT, al-
though donor-type Thy-1 + cells are detectable in the tolerant mice, the large
majority ofT cells are of recipient type .
TCell Receptor Expression in Tolerant Mice.
￿
Recently, anumber ofreportshaveshown
that the expression of certain TCRa chains correlates with the reactivity to Mls
antigens (16, 20, 21) . Thus, V06* matureT cells are absent in Mlsa strain of mice,
whereas they constitute 10-15% oflymph node cells in Mlsb mice . Since lympho-
cytes from Mlsb animals can initiate a strong proliferation response against Mlsa
FIGURE 5 .
￿
VS6* T cells are not
deleted from MLSb mice tolerant
of MLSa grafts . Mouse lymph
node cells were double stained with
YTS 191.1 (CD4) or YTS 169.4
(CD8) and biotinylated 44-22-1
(TCR VS6), followed by FITC-
NORIG 7.16 (anti-rat IgG26) and
streptavidin-phycoerythrin . The
percentage of each positive popu-
lation is given in respective regions.
(A, B) CBA mouse received mAb
treatment only ; (C, D) CBA/Ca
mice that had been tolerized with
AKR/JBM andCD4+CD8 mAb
injection, carrying AKR skin for
>120 d . The same reagents stained
<1% V06* cells in controlAKR/J
mice (not shown) . Data represent
oneoffour animals tested, all with
similar staining patterns .
Animals Treatment
Percent Thy-1 .1
(donor type)
Percent
(host
Thy-1 .2
type)
CBA/Ca mAb +AKR/J BM 3.5 t 0.5 11 .9 t 1 .6
CBA/Ca mAb 1 .7 t 0.4 13 .8 t 2 .7
CBA/Ca AKR/J BM 1 .7 t 0.7 28 .5 t 0.5
AKR/J none 31 t 0.6 1 .1 t 0.1790
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FIGURE 6.
￿
In vitro unresponsive-
ness of CBA mouse spleen cells
tolerant to AKR. 5 x 105 spleen
cells from mice described in Fig. 5
were incubated with 5 x 105 3,000-
rad irradiated AKR (hatched bar) or
BALB/c (open bar) spleen cells.
Proliferation was measured by day
4 IUdR incoperation. Negative
controls (solid bar) were responder
cells incubated with medium only.
cells, it has been postulated that TCR V06 may react with Mlsa antigen. It follows
that in Mlsa mice the lack ofV06' cells is due to clonal deletion during thymocyte
maturation. In thepresent study, we measured theexpression ofV06 chainin CBA/Ca
(Mlsb) recipients rendered tolerant of AKR/J (Mlsa), carrying AKR skin for
>120 d. Lymph node cells from tolerant mice were stained with an antiV06 mAb
44-22-1 (reference 16) together with mAbs to CD4 or CD8 antigens for two-color
flow cytometry. Much to our surprise, these animals had normal levels of V06'
lymph node cells (Fig. 5) and spleen cells (not shown). The percentages of CD4and
CD8 population among these cells were similar to age-matched control mice given
mAb treatment only (Fig. 5). However, spleen cells from these tolerant mice were
unresponsive in vitro to AKR/J stimulation as measured by proliferation analysis
(Fig. 6), and T cell chimerism was consistently detectable (Table IX).
.. 3
Discussion
We have documented here a number of examples where transplantation tolerance
could be achieved in adult animals by introduction of allogeneic BM. In these ex-
amples, alloreactivity (graft-vs.-host and host-vs.-graft) had been prevented by in-
jection ofCD4 and CD8 mAbs. There are obviousand probably plausible analogies
between these findings and the model of classical transplantation tolerance in the
neonate. The neonatal mouse lacks immunocompetent peripheral T cells at birth
and arguably our use of mAbs also recreated in the adult a "tolerance permissive
environment." Our findings have been based on studies usingdonor-recipient com-
binationsdiffering in multiple minortransplantation antigendifferences and in the
case of B10.A onto CBA/Ca, a further class I MHC (H-2D) difference. However,
the same regime did not allowus to achievetolerance in complete MHC (+ minors)
mismatched combinations (e.g., BALB/c into CBA or B10.BR into BALB/c). In the
past we had to include some level of irradiation (600 rad) in addition to C134 and
CD8 mAbs to guarantee successful marrow engraftment and tolerance in complete
H-2 plus minor mismatched situation. With this level of irradiation nearly all the
white cells that regenerated were of donor type (22).
The development of chimerism and tolerance was dependent on the preventionQIN ET AL.
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of alloreactivity in both the donor and recipient T cell populations. The presence
of T cells in the B10.BR, but not the (B10.BR x CBA/CA)Fi, marrow/spleen in-
oculum resulted in far fewer CBA/Ca recipients becoming tolerant. It was possible
that although the recipients were treated with the CD4 and CD8 mAbs, this was
insufficient to adequately cope with all the donor T cell alloreactivity. A similar
phenomenon of T cell interference has also been observed in ALS + BM-induced
unresponsiveness (23). There are two possible explanations for how T cells inter-
fered with engraftment. The first is that donor alloreactive cells were inhibitory to
donor hemopoiesis necessary to establish chimerism. The second is that donor al-
loreactivity somehow helped residual host lymphocytes to resist or reject the donor
stem cells. The available data do not distinguish between the two possibilities. This
finding seems to contradict previous data that suggested a role of donor T cells in
helping engraftment rather than hindering it (24). However, in those studies, host
resistance and hemopoiesis had been further compromised by priorirradiation . We
are presently investigatingto what extent these findings are applicable to otherstrain
combinations.
We observed that both the recipient CD4 and CD8 subsets were independently
capable of resisting B10.BR donor marrow and that both had to be controlled to
ensure tolerance in the B10.BR into CBA/Ca combination. Surprisingly the CD8
subset could be "controlled" with rIgG2b F(ab')2 CD8 mAb fragments or a non-
depleting rIgG2a mAb, suggesting that depletion of this subset was not essential
for tolerance. The failure of tolerance with F(ab')2 fragments of rIgG2b CD4 must
have been due to the fact that CD4 mAb fragments had simply not been used in
sufficient quantity. Surprisingly, the combination of nondepleting CD4 and CD8
rIgG2a mAbs was unable to create tolerance, although tolerance was possible when
either mAb was combined with thecomplementary rIgG2b mAbs. Notwithstanding
this, the importance of these findings is the demonstration that both mature CD4
and CD8 cells are tolerizable without depletion. In a different model of tolerance
to HGG and rat IgG, we and others have observed that F(ab')2 fragments of rIgG2b
or intact rIgG2a CD4 mAbs were similarly tolerance permissive for CD4 cells (12,
18). Nondepleting LFA-1 mAbs could also create a tolerogenic enviroment where
concomitant administration of HGG resulted in long-term toleranceto that antigen
(12). The inescapable conclusion of these and other studies (25) is that peripheral
CD4 and CD8 cells may still have the choice of turning OFF as well as ON . The
outcome would seem to be affected by blockade of CD4, CD8, LFA-1, and perhaps
other surface molecules e.g., IL-2 receptors. Perhaps these molecules are crucial to
the signaling that determines ON or OFF, or alternatively, when T cells recovering
from mAbblockade ofthese functional molecules encounter antigens in the absence
of a helpful influence, the confrontation with antigen may lead to tolerance.
Natural and neonatal tolerance to Mlsa antigens has been reported to be as-
sociated with deletion of V06+ cells (16, 20, 26) However, Fowlkes et al. (27) have
shown that prolonged administration of CD4 mAb prevented the V06+ cell dele-
tion at the CD4+CD8+ precursor stage. Our studies have looked at V06 expres-
sion many weeks aftertolerance inductionwith mAb therapy, and have not revealed
depletion of V06 cells, although these CBA/Ca (Mlsb) mice showed unresponsive-
ness to AKR/J (Mlsa) antigens. This finding is not compatible with clonal deletion
unless the V06 cells we detected had been derived from a cell population that was792
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Mlsa nonreactive. On the other hand, these data may suggest that functional anergy
may also contribute to atolerant state, as has been reported forthe Bcell lineage(28).
Traditionally amajor featureofmarrow transplantation has been theneed to create
"space" for a successful graft (29). The "space" concept arose from the need to ir-
radiate or administer myelotoxic agents to achieve successful engraftment. In this
study it would appear that no new "space" had to be created for donor marrow to
engraft and to establish toleranceto donorantigens. Chimerism of T and Blympho-
cytes could be achieved with the use of only CD4 and CD8 mAbs that would spare
hemopoietic stem cells.
We can categorize the circumstances in which the BM + mAb protocol failed
to achieve tolerance into two groups; those where chimerism was established and
those whereit was not. Those lackingchimerism we consider as examples of residual
resistance/rejection. For strong MHC differences our present capacity to control al-
loreactivity in vivo with mAbs alone may be limited. There are well-documented
examples ofresistance mechanisms otherthan CD4 and CD8 cells that can prevent
marrow engraftment (30). These may be controlled by the use of additional mAbs
or irradiation. Those situations where chimerism is insufficient to guarantee toler-
ance to skin grafts may represent instances where a tissue (skin)-specific antigen
is simply insufficiently represented in the small percentage of chimeric donor
hemopoietic cells. The creation of physical space might permit accumulation of
sufficient levels of that "minor" antigen to reach tolerogenic thresholds. As tolerance
to minors is MHC restricted (31-33), there is a requirement that minors must be
presented on appropriate APC for tolerance to occur. As is the case for any other
protein, minor antigens can be processed and represented on other cells for toler-
ance. Our studies have reinforced these findings (i.e., tolerance can be mediated by
donor minors processed and presentedon host MHC); and they suggest an explana-
tion ofthe "tissue-specific antigen" phenomenon. Simply put, the chance ofapartic-
ular tissue-specific minor to tolerize T cells is increased the more APCs there are
available to process andpresent it. In the normal situation, thehemopoietic system
is 100% host and 100% of skin is host. Therefore, maximal opportunity for pro-
cessing and presentation for tolerance exists. In neonatal tolerance or in the present
model of adult mAb-facilitated tolerance, only a fraction of thehemopoietic system
is donortype, so tolerance to all minor antigens may not always be possible. Irradia-
tion of the recipient would then allow donor cells to accumulate to levels sufficient
for tolerance induction.
Although it seems easy to induce toleranceto minor class I antigens with the present
mAb therapy, tolerance across full MHC incompatibility is still difficult without ir-
radiation. Our recent work has shown that the inclusion ofan anti-LFA-1 mAb into
this cocktail allows tolerance with chimerism in complete H-2 mismatch combina-
tion with only 300 rad of irradiation (Benjamin, R., et al., manuscript in prepara-
tion). It may be that the addition of yet other mAbs may make it feasible to control
rejection to produce tolerance without any need to use irradiation or myelotoxic
drugs. This would have obvious benefits for clinical practice.
Summary
Transplantation tolerance across histoincompatibilities in multiple non-H-2 minors
(B10.BR into CBA/Ca) and "minor" plus H-2D (B10.A into CBA/Ca) antigens hasQIN ET AL.
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been achieved successfully by combined adult bone marrow transplantation and treat-
ment with CD4 and CD8 mAbs. The tolerant state was confirmed by permanent
acceptance of donor strain skin grafts, and in vitro unresponsiveness to donor cells.
Tolerance was associated with partial donor chimerism to various degrees. Toler-
ance to minor transplantation antigens induced in this manner was restricted to
recipient-type MHC . The possibility was raised that tolerance resulted, at least in
part, from clonal anergy rather than deletion.
We thank Dr. Hans Hengartner for generously providing the antiV/06 mAb, Professor Robin
Coombs for advice on hemagglutination analysis, Dr. Mike Clark for useful discussions, and
Dr. "Zip" Kruger-Gray for help in flow cytometry.
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